HomeScreenerMDNAProfile
C
61/100

Medicenna Therapeutics

MDNAIL-4/IL-13 Oncology
📋
Analyst Summary
✓ VERIFIED2026-04-11

Medicenna Therapeutics (MDNA) is the lead sponsor of 1 active clinical trials listed on ClinicalTrials.gov[3], including 1 Phase 2[1], 1 Phase 1[2].

No Form 4 insider filings for MDNA were recorded at the SEC in the past 30 days[4].

Sources

  1. ClinicalTrials.gov (2026-04-11)
  2. ClinicalTrials.gov (2026-04-11)
  3. ClinicalTrials.gov (2026-04-11)
  4. SEC EDGAR (2026-04-11)
🔬
Clinical Trials
1
NCT05086692Advanced Solid Tumor, Unresectable Solid Tumor, Clear Cell Renal Cell Carcinoma, Triple Negative Breast Cancer, Non-Small Cell Lung Cancer Squamous, Non-Small Cell Lung Cancer Non-squamous, Colorectal Cancer (MSI-H), Gastric Cancer, Cervical Cancer, Basal Cell Carcinoma, Bladder Cancer, Merkel Cell Carcinoma, Squamous Cell Carcinoma of Head and Neck, Cutaneous Squamous Cell Carcinoma, Pleural Mesothelioma, Esophageal Cancer, Endometrial Carcinoma, Solid Tumor, Solid Tumor, Adult, MSI-H Solid Malignant Tumor, Cancer With A High Tumor Mutational Burden, Epithelial Ovarian Carcinoma, Primary Peritoneal Cancer, Gastroesophageal Junction (GEJ) Cancer, Acral Melanoma, Mucosal Melanoma, Cutaneous Melanoma, DMMR Solid Malignant Tumor, Fallopian Tube Cancer, Ovarian Cancer, MSI-H Cancer, DMMR Cancer, Pancreas Adenocarcinoma (MSI-H), Skin Cancer, Viral Cancer, Cervical Cancers, Endometrial Cancer
Source ↗
clinicaltrials_gov · Retrieved 2026-04-11
👤
Insider Activity
1
0 filings
Source ↗
sec_edgar · Retrieved 2026-04-11
Not financial advice. BiotechSigns profiles are AI-generated from verified public sources (ClinicalTrials.gov, SEC EDGAR) and are for informational purposes only. Always do your own due diligence before making investment decisions.
Score Breakdown
Score Trend
2026-04-132026-06-02
Signal Summary
PDUFA Dates0
Insider Filings1
Clinical Trials1
Data Provenance
clinical trial1 verified
insider buy1 verified
trial count3 verified
Every claim backed by source URL from ClinicalTrials.gov or SEC EDGAR